PFKFB3 and pulmonary arterial hypertension: Notably, genetic or pharmacologic inactivation of PFKFB3 abrogated inflammation in various disease models such as and LPS and pulmonary hypertension, linking PFKFB3-driven glycolysis to endothelial proinflammatory pathways (57, 60).